By Mill Chart
Last update: Jul 29, 2025
ALKERMES PLC (NASDAQ:ALKS) reported second-quarter 2025 financial results that exceeded analyst expectations, driving a notable pre-market rally. The biopharmaceutical company posted revenue of $390.7 million, surpassing the consensus estimate of $348.4 million, while diluted GAAP earnings per share (EPS) of $0.52 also came in ahead of the projected $0.41.
The stock surged 7.8% in pre-market trading, reflecting investor optimism following the earnings beat. Despite recent weakness—shares were down 1.9% over the past week and 11.9% over the last two weeks—the strong quarterly results appear to have reversed some of the negative sentiment.
Analysts expect Q3 2025 revenue of $360.8 million and full-year sales of $1.412 billion, which Alkermes’ current performance suggests it could meet or exceed. The company’s reiteration of its full-year outlook aligns with these projections, reinforcing stability in its financial trajectory.
For a deeper dive into Alkermes’ earnings and future estimates, visit the earnings estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
26.55
-0.05 (-0.19%)
Find more stocks in the Stock Screener